Similarly, in an ongoing clinical trial with anti-CD123 antibody-drug conjugate IMGN632, no endothelial or marrow toxicity was seen33,34 in AML or BPDCN patients, supporting acceptable safety targeting CD123. Here, IL3RA is linked to acute myeloid leukemia.